ID   SU/SR
AC   CVCL_UI51
DR   cancercelllines; CVCL_UI51
DR   Wikidata; Q98132865
RX   PubMed=18783828;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=18783828).
CC   Sequence variation: Mutation; HGNC; HGNC:76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (PubMed=18783828).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C114819; Adult B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UI50 ! SU-Ph2
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 11
//
RX   PubMed=18783828; DOI=10.1016/j.leukres.2008.07.023;
RA   Hirase C., Maeda Y., Takai S., Kanamaru A.;
RT   "Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin:
RT   possible clinical application of mTOR inhibitor.";
RL   Leuk. Res. 33:450-459(2009).
//